OVERVIEW

Thursday, April 9, 2026 | 2:00 p.m. - 3:00 p.m. Eastern

As the U.S. cell and gene therapy (CGT) market continues to evolve, the financial exposure tied to multi-million-dollar claims remains very real for self-insured employers and the advisors who support them.  Among FDA-approved CGTs, CAR T-cell therapies in particular have emerged as a significant high-cost risk category, with individual claims often approaching or exceeding $1 million.

For health benefit brokers and consultants, understanding how these therapies impact plan design, stop-loss strategy, reinsurance strategies, and total cost of care is increasingly critical.

SIIA's Cell and Gene Task Force is pleased to present a fireside-style webinar featuring a distinguished panel of experts representing employer, manufacturer, clinical, and patient perspectives. The discussion will examine the evolving CGT landscape, financial risk considerations, access challenges, and practical strategies brokers and benefit consultants can use to help self-insured employer clients navigate high-cost therapies with greater confidence and predictability. 

• Complimentary for SIIA members
• $100 for non-members